Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Economic model of a birth cohort screening program for hepatitis C virus.

McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC.

Hepatology. 2012 May;55(5):1344-55. doi: 10.1002/hep.25510. Epub 2012 Mar 18.

PMID:
22135116
2.

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM.

Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4.

PMID:
22056542
3.

The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.

McEwan P, Ward T, Yuan Y, Kim R, L'italien G.

Hepatology. 2013 Jul;58(1):54-64. doi: 10.1002/hep.26304. Epub 2013 May 27.

PMID:
23389841
4.

Cost-effectiveness and population outcomes of general population screening for hepatitis C.

Coffin PO, Scott JD, Golden MR, Sullivan SD.

Clin Infect Dis. 2012 May;54(9):1259-71. doi: 10.1093/cid/cis011. Epub 2012 Mar 12.

5.

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.

Saab S, Hunt DR, Stone MA, McClune A, Tong MJ.

Liver Transpl. 2010 Jun;16(6):748-59. doi: 10.1002/lt.22072.

6.
7.

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A; WEF Study Group..

J Hepatol. 2013 Oct;59(4):658-66. doi: 10.1016/j.jhep.2013.05.019. Epub 2013 May 23.

PMID:
23707373
8.

Economic assessment of an anti-HCV screening program in Italy.

Ruggeri M, Coretti S, Gasbarrini A, Cicchetti A.

Value Health. 2013 Sep-Oct;16(6):965-72. doi: 10.1016/j.jval.2013.07.005.

9.

Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N.

Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. Review.

10.

Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.

Venditti LN, Venditti CP, Berry GT, Kaplan PB, Kaye EM, Glick H, Stanley CA.

Pediatrics. 2003 Nov;112(5):1005-15.

PMID:
14595039
11.

Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B.

Hutton DW, Tan D, So SK, Brandeau ML.

Ann Intern Med. 2007 Oct 2;147(7):460-9.

PMID:
17909207
12.

HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations.

Tramarin A, Gennaro N, Compostella FA, Gallo C, Wendelaar Bonga LJ, Postma MJ.

Curr Pharm Des. 2008;14(17):1655-60.

PMID:
18673188
13.

Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA.

Clin Infect Dis. 2012 Jul;55(2):279-90. doi: 10.1093/cid/cis382. Epub 2012 Apr 4.

14.

Cost effectiveness of screening immigrants for hepatitis B.

Wong WW, Woo G, Jenny Heathcote E, Krahn M.

Liver Int. 2011 Sep;31(8):1179-90. doi: 10.1111/j.1478-3231.2011.02559.x. Epub 2011 Jun 14.

PMID:
21745300
15.

Cost-effectiveness of expanded newborn screening in Texas.

Tiwana SK, Rascati KL, Park H.

Value Health. 2012 Jul-Aug;15(5):613-21. doi: 10.1016/j.jval.2012.02.007. Epub 2012 Jun 7.

16.

Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.

He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, Chhatwal J.

Ann Intern Med. 2016 Jan 19;164(2):84-92. doi: 10.7326/M15-0617. Epub 2015 Nov 24.

17.

Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.

Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Mühlberger N, Wright D, Zeuzem S, Siebert U.

Eur J Public Health. 2009 Jun;19(3):245-53. doi: 10.1093/eurpub/ckp001. Epub 2009 Feb 5. Review.

PMID:
19196737
18.

Cost-effective analysis of screening for biliary atresia with the stool color card.

Mogul D, Zhou M, Intihar P, Schwarz K, Frick K.

J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):91-8. doi: 10.1097/MPG.0000000000000569.

PMID:
25221934
19.

An evidence of high prevalence of Hepatitis C virus in Faisalabad, Pakistan.

Ahmad N, Asgher M, Shafique M, Qureshi JA.

Saudi Med J. 2007 Mar;28(3):390-5.

PMID:
17334466
20.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124

Supplemental Content

Support Center